By Kuldip K. Ambastha
On Friday, July 16, 2021, the stock of Moderna, Inc. (MRNA) was up by +10.3% for the trading day. Moderna, a biotechnology company, has been highly successful in its efforts to develop a coronavirus (COVID-19) vaccine. Late on Thursday, July 15, 2021, S&P Dow Jones Indices announced that Moderna will become a component of the S&P 500 Index in the next week. Moderna will become a part of the S&P 500 Index after only one quarter (the most recently closed quarter) of reported net profit as a public company. Due to the company’s success with its coronavirus vaccine offering, the stock price of Moderna has seen a significant increase in the recent past. Going forward, Wall Street equity research analysts are nonetheless expecting even more upward movement in the stock price. Aside from the coronavirus vaccine already in place, Moderna is looking into making more vaccines and drugs around Zika, influenza (flu), HIV / AIDS, and cancer. For our past coverage of Moderna, see below:
What Caught Our Attention in the Investment World? – Week of February 24-28, 2020
Keywords – Moderna, Inc., Moderna, MRNA, S&P Dow Jones Indices, S&P 500 Index, S&P 500, coronavirus, COVID-19, vaccine, USA, biotechnology, biotech, Zika, influenza, flu, HIV, AIDS, health, wellness.
Disclosure – The principals of Ambastha Financial LLC have a short option position in MRNA. The clients of Ambastha Financial LLC have no positions in MRNA.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2021 – Ambastha Financial LLC.